Significant progress in understanding T cell signalling, particularly with respect to T cell co-receptors such as the co-stimulatory receptor CD28, has been made in recent years. This knowledge has ...
The numbers of T-cell receptors (TCRs) engaged, as well as the time of interaction with the major histocompatibility complex (MHC)–peptide complexes, determine whether T-cell activation occurs.
Adding CD28 costimulation to cord blood-derived chimeric antigen receptor (CAR) natural killer (NK) cells targeting CD70+ cancers significantly enhanced antitumor efficacy and long-term cytotoxicity ...
Bidirectional signaling along the B7–CTLA-4 coreceptor pathway enables reciprocal conditioning of T cells and dendritic cells. Although T cells can instruct dendritic cells to manifest tolerogenic ...
A prospective phase II study to evaluate olaparib plus abiraterone and prednisone combination therapy in metastatic hormone sensitive prostate cancer patients with HRR gene mutation: Updated analysis ...
-- Research collaboration focused on the discovery of novel bispecific antibodies directed toward the CD28 co-stimulatory receptor and an undisclosed prostate tumor target -- -- Xencor receives $50 ...
HAYWARD, Calif.--(BUSINESS WIRE)--Rondo Therapeutics, a privately held biopharmaceutical immuno-oncology company pioneering the development of next-generation T cell-engaging bispecific antibodies for ...
Alpine Immune Sciences turned heads a year ago when AbbVie formed a deal with the company worth up to $805 million in milestone payments for a first-in-class lupus drug that inhibits a protein on the ...
With analysts looking for a meaningful increase in the number of responses for Regeneron's phase 1/2 solid tumor trial, a fresh data slice shows just one complete response across 94 patients.
From the Riddell, Paulovich Labs, Clinical Research Division and Gottardo Lab, Vaccine and Infectious Disease Division. In order to identify why the different costimulatory domains have differing ...
Hypervigilance: A phase Ib clinical trial to optimize risk-benefit of nezastomig (PSMAxCD28 costimulatory bispecific antibody) plus cemiplimab (anti-PD-1) in patients with metastatic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results